Cellevate has announced the closure of its recent investment round, securing a total of 39 million SEK.
The round was led by Industrifonden, in syndication with the European Innovation Council Fund (EIC Fund) and Onsight Ventures.
“We are thrilled to have gained tremendous support from such a strong syndicate of investors, who share our vision of transforming biomanufacturing. This investment represents a significant milestone for our company and a valuable endorsement for the potential of our Cellevat3d nanotechnology, allowing us to take the next pivotal steps on our journey. The financing will enable us to accelerate commercialization and to progress towards our goal of making a lasting impact in the global healthcare landscape,” says Laura Chirica, CEO Cellevate.
A mission of driving innovation in biomanufacturing
The new capital will be instrumental in driving Cellevate’s plans for commercialization and facilitating a global product launch, it states. Specifically, the funds will be allocated towards growing the team, establishing robust manufacturing capabilities, and launching the company’s nanofiber-based products in key markets.
“We are impressed by Cellevate’s groundbreaking technology and the team behind it. This investment reflects our commitment to supporting pioneering companies that have the potential to revolutionize the industry. We look forward to a long-term partnership with Cellevate as they advance their mission of driving innovation in biomanufacturing,” says Mala Valroy, Investment Manager at Industrifonden and incoming board member of Cellevate.
Photo of Cellevate Leadership team Maximilian Ottosson, Co-founder and COO Laura Chirica, CEO Albin Jakobsson, Co-founder and CTO
